Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Beule, Dieter Dr. (2) Cakmak-Görür, Nese Dr. (1) Daniel, Peter Prof. Dr. (2) Dhamodaran, Arunraj (1) Kammertöns, Thomas Dr. (5) Kopp, Joachim Dr. (2) Leisegang, Matthias Prof. Dr. rer. nat. (3) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Pezzutto, Antonio Prof. Dr. (5) Poncette, Lucia (1) Rhein, Simone Dr. (1) Siffrin, Volker (1) Uckert, Wolfgang Prof. Dr. (4) Willimsky, Gerald Dr. (4) (-) Blankenstein, Thomas Prof. Dr. (23) Bioinformatics and Omics Data Science (1) Biologie maligner Lymphome (11) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (23) Proteom Dynamik (1) Strukturbiologie Membran-assoziierter Prozesse (1) Systembiologie von Gen-regulatorischen Elementen (1) Translational Bioinformatics (2) Translationale Onkologie solider Tumore (1) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) (-) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (1) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (3) (-) 2015 (3) 2016 (4) 2017 (6) 2018 (4) (-) 2019 (6) 2021 (4) 2022 (6) 2023 (4) 2024 (2) 23 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Molekulare Immunologie und Gentherapie 1997201120152019 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 1997 / Eur J Immunol Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency S. Cayeux G. Richter C. Becker C. Beck A. Aicher A. Pezzutto B. Doerken T. Blankenstein 15. Juli 1997 / J Immunol Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte- macrophage colony-stimulating factor gene-modified tumor cells Z. Qin G. Noffz M. Mohaupt T. Blankenstein 01. Januar 1997 / Exp Hematol Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells A. Aicher J. Westermann S. Cayeux G. Willimsky K. Daemen T. Blankenstein W. Uckert B. Doerken A. Pezzutto 01. Januar 1997 / Methods Mol Med Methods for use of cytokine gene-modified tumor cells in immunotherapy of cancer Z. Qin T. Blankenstein 15. Oktober 1997 / J Immunol Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis P.T. Daniel A. Kroidl S. Cayeux R.C. Bargou T. Blankenstein B. Doerken 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein 13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Nächste Seite Next › Letzte Seite Last »
01. Januar 1997 / Eur J Immunol Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency S. Cayeux G. Richter C. Becker C. Beck A. Aicher A. Pezzutto B. Doerken T. Blankenstein
15. Juli 1997 / J Immunol Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte- macrophage colony-stimulating factor gene-modified tumor cells Z. Qin G. Noffz M. Mohaupt T. Blankenstein
01. Januar 1997 / Exp Hematol Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells A. Aicher J. Westermann S. Cayeux G. Willimsky K. Daemen T. Blankenstein W. Uckert B. Doerken A. Pezzutto
01. Januar 1997 / Methods Mol Med Methods for use of cytokine gene-modified tumor cells in immunotherapy of cancer Z. Qin T. Blankenstein
15. Oktober 1997 / J Immunol Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis P.T. Daniel A. Kroidl S. Cayeux R.C. Bargou T. Blankenstein B. Doerken
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein